Cumberland Pharmaceuticals Inc. (CPIX)
| Market Cap | 68.35M +1.0% |
| Revenue (ttm) | 41.94M +2.1% |
| Net Income | -7.38M |
| EPS | -0.50 |
| Shares Out | 14.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 77,812 |
| Open | 4.540 |
| Previous Close | 4.680 |
| Day's Range | 4.430 - 4.670 |
| 52-Week Range | 1.850 - 6.265 |
| Beta | -0.06 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 5, 2026 |
About CPIX
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sod... [Read more]
Financial Performance
In 2025, CPIX's revenue was $44.52 million, an increase of 17.57% compared to the previous year's $37.87 million. Losses were -$2.84 million, -56.23% less than in 2024.
Financial StatementsNews
CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
Enters into Strategic Transaction, unlocking $100 million in value Sharpens focus on Orphan Drug candidates to address unmet medical needs NASHVILLE, Tenn., May 5, 2026 /PRNewswire/ -- Cumberland Phar...
Cumberland Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 revenue rose 5% year-over-year (excluding a prior milestone), with positive cash flow and a net loss of $3.3 million. A $100 million Apotex deal will shift focus to pipeline innovation, while FDA approvals and new product launches drive momentum.
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-104 2 , designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium ...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
NASHVILLE, Tenn., April 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2026 financi...
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
2025 was a year of tenacity, strategic transactions and building traction for RedHill Talicia® business transformed: Formation of Talicia Holdings Inc. (THI) and the U.S. co-commercialization partners...
Cumberland announces transaction to integrate commercial business with Apotex
Cumberland (CPIX) has entered into an agreement with an affiliate of Apotex, a Canadian based pharmaceutical company, to integrate their branded U.S. businesses. Under the terms of the agreement, Apot...
Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex
Transaction unlocks $100 million in value for Cumberland Sharpens focus on Orphan Drug Candidates to address Unmet Medical Needs NASHVILLE, Tenn., April 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuti...
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib [1] as potential add-on thera...
Cumberland receives FDA approval for expanded Caldolor injection
Cumberland (CPIX) has received approval from the FDA for an expanded indication for its Caldolor – ibuprofen – Injection product. The indication now includes the management of postoperative pain, and…
CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE
A Safe and Effective Non-Opioid Pain Management Solution NASHVILLE, Tenn., April 16, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today anno...
Cumberland announces launch of new Sancuso website
Cumberland (CPIX) Pharmaceuticals announced the launch of its new Sancuso website. “The website is designed to provide health care professionals and patients with enhanced access to educational resour...
Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting
Sancuso – the Difference Between Life and Living NASHVILLE, Tenn., March 17, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company today announced the...
CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH
Cumberland to highlight 2025 financial, international, portfolio and clinical progress NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharm...
Cumberland Pharmaceuticals Earnings Call Transcript: Q4 2025
2025 saw 18% revenue growth, improved adjusted earnings, and global expansion, led by Vibativ, Sancuso, and the launch of Talicia. The pipeline advanced with ifetroban's breakthrough results and new FDA designations, while 2026 targets continued double-digit growth.
Cumberland and THI announce U.S. commercialization of Talicia
RedHill Biopharma announced that the full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings, or THI, and Cumberland (CPIX) Pharmaceuticals, ...
RedHill Biopharma announces full sales and operational launch of Talicia
RedHill Biopharma (RDHL) announced that the full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings, or THI, and Cumberland Pharmaceuticals (...
Joint U.S. Commercialization of RedHill's Talicia® Commences
The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and...
CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®
NASHVILLE, Tenn., Feb. 25, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, today announced...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE
NASHVILLE, Tenn., Feb. 24, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its 2025 financial results and ...
Cumberland receives fast track designation for DMD oral therapy from FDA
Cumberland (CPIX) Pharmaceuticals announced that the FDA has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in Duchenne muscular dystrophy, or DMD,…
Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program
NASHVILLE, Tenn., Feb. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today ...
CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT
NASHVILLE, Tenn. , Dec. 8, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), today announced an important update regarding its Caldolor® (ibuprofen) Injection.
CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH
NASHVILLE, Tenn. , Nov. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands de...
Cumberland Pharmaceuticals Earnings Call Transcript: Q3 2025
Q3 revenue reached $8.3M, with year-to-date revenue up 12% to $30.9M. Expanded the portfolio with Talicia, launched Vibativ internationally, and advanced Ifetroban clinical programs. Cash flow from operations was $5M, and total assets stood at $66M.
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE
NASHVILLE, Tenn. , Oct. 28, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2025 financi...